Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07604220 · ClinicalTrials.gov registry record
Exosome-based Omic Signatures of Disease Activity in Cardiac Sarcoidosis (EXODACS)
A clinical trial, sponsored by Mayo Clinic.
- Not yet
- Registry status
- 115
- Enrollment target
NCT07604220: Clinical Trial study, sponsored by Mayo Clinic.
NCT07604220 is a clinical trial that has not yet begun recruiting, run by Mayo Clinic. The registered enrollment target is 115 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07604220 has not yet begun recruiting, sponsored by Mayo Clinic.
- NOT YET RECRUITING
- Registry status
- 115 participants
- Enrollment target
Study Summary
The purpose of this study is to develop a prospective cohort of patients with and without cardiac sarcoidosis as well as active and inactive disease to develop a prospective biobank from which exosome analysis of peripheral blood will derive unique biomarkers of disease activity in cardiac sarcoidosis.
Primary Outcome
Biomarker validation will be defined as ability to discriminate active from inactive or quiescent disease as assessed by FDG-PET
Interventions
- OTHER Exosome Analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-07 |
What is known before NCT07604220 opens enrollment
NCT07604220 is an observational study that tracks outcomes without assigning an intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Exosome Analysis is the first listed.
NCT07604220 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07604220 about?
NCT07604220 is a clinical study titled "Exosome-based Omic Signatures of Disease Activity in Cardiac Sarcoidosis (EXODACS)". The purpose of this study is to develop a prospective cohort of patients with and without cardiac sarcoidosis as well as active and inactive disease to develop a prospective biobank from which exosome analysis of peripheral blood will derive unique biomarkers of disease activity in cardiac sarcoidos...
What is the current status of trial NCT07604220?
This trial is currently not yet recruiting. The enrollment target is 115 participants. The study started on 2026-07. Estimated completion is 2028-07.
What interventions are being tested in trial NCT07604220?
The interventions under investigation include: Exosome Analysis (OTHER).
Who is sponsoring clinical trial NCT07604220?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia